Distinct Inflammatory Changes of the Pancreas of Slowly Progressive Insulin-dependent (Type 1) Diabetes

Kaoru Aida, MD, PhD,*, Tomoyasu Fukui, MD, PhD,†† Erika Jimbo, BS,‡ Soroku Yagihashi, MD, PhD,§ Akira Shimada, MD, PhD,∥ Yoichi Oikawa, MD, PhD,∥∥ Yasumichi Mori, MD, PhD,¶ Takeshi Fujii, MD, PhD,# Yoriko Nishida, MD, PhD,** Rikako Koyama, MD, §§ Tetsuro Kobayashi, MD, PhD,†††

Objective: The aim of this study was to identify the distinct pathological changes on the endocrine and exocrine pancreas of slowly progressive insulin-dependent diabetes mellitus (SPIDDM) or latent autoimmune diabetes in adults.

Methods: The pancreases from 12 islet autoantibody–positive SPIDDM patients and 19 age-matched subjects with no diabetes were examined histologically for islet inflammation/insulitis, expressions of cytokines, and enterovirus VP1 protein, exocrine pancreatic inflammation, pancreatic ductal changes, major histocompatibility complex class I hyperexpression, and amylin-positive amyloid in the islets.

Results: Insulitis dominant for CD8+ T-cells and CD68+ macrophages was observed in all SPIDDM cases irrespective of duration of diabetes and weight of residual beta cells. Major histocompatibility complex class I hyperexpression in islet inflammation, dilated pancreatic ducts, and periductal fibrosis. As many as 75% (9/12) of pancreases had pancreatic intraepithelial neoplasia, which is assumed to be associated with ductal obstruction/narrowing and exocrine pancreatic inflammation, in SPIDDM. Amylin-positive amyloid deposition was not detected in SPIDDM.

Conclusions: Persistent insulitis with preserved beta cells and major histocompatibility complex class I hyperexpression and exocrine pancreatic inflammation with pancreatic intraepithelial neoplasia are distinct histological features of SPIDDM pancreas.

Key Words: chronic pancreatitis, GADAbs, insulitis, PanIN, SPIDDM

(Pancreas 2018;47: 1101–1109)

Slowly progressive insulin-dependent (type 1) diabetes (SPIDDM),1–4 later also referred to as latent autoimmune diabetes in adults,5,6 is the most prevalent clinical subtype of type 1 diabetes mellitus.6 Late age at onset; progressive beta cell failure, which is associated with an initial non–insulin-requiring state and an ultimate insulin-dependent state over several years; and persistent islet cell autoantibodies including glutamic acid decarboxylase autoantibodies (GADAbs) and islet cell antibodies (ICAs) are characteristic clinical features of this subtype of type 1 diabetes.7,8 Slowly progressive insulin-dependent diabetes or latent autoimmune diabetes in adults is a conceptual phenotype between classic acute-onset type 1 diabetes (AT1DM) and type 2 diabetes (T2DM).6 Intervention trials to prevent progressive beta cell failure using insulin, metformin, DPP4 inhibitors, and/or GLP-1 analogs are currently challenging clinical issues in SPIDDM.9–12 However, reports on pathological changes in the pancreas of SPIDDM are lacking; the presence or absence of islet inflammation, a sign of type 1 diabetes, and islet amyloid deposition, a sign of T2DM, are obscure.13 Exocrine pancreatic inflammation and atrophy in type 1 diabetes are currently under discussion.14–16 To the best of our knowledge, this is the first systematic study of in situ changes of islets and exocrine pancreatic tissues in SPIDDM pancreases positive for GADAbs and ICAs. The pathological features including insulitis, profiles of islet-infiltrating mononuclear cells (MNCs), major histocompatibility complex (MHC) class I hyperexpression, pancreatic ductal changes, and exocrine inflammation of SPIDDM were studied by comparison with age-matched control subjects with no diabetes.

MATERIALS AND METHODS

Subjects

Pancreatic tissue acquisition and data collection were performed between 1982 and 2014 and partly published previously.17–20 The pancreatic samples were obtained from Toranomon Hospital (Tokyo, Japan), University of Yamanashi (Yamanashi, Japan), Saitama Social Insurance Hospital (Saitama, Japan), and Tokyo Saiseikai Central Hospital (Tokyo, Japan). Twelve pancreases from SPIDDM patients and 19 age-matched control subjects with no diabetes were examined to minimize age-related bias (Table 1).
All subjects were of Japanese ethnic origin. This report presents the results from the pancreases obtained from autopsied samples, except for 1 biopsied case (case SP-10). Patients with SPIDDM had adult-onset diabetes with a non–insulin-requiring period of more than 3 months, as well as GADAbs and/or ICAs (Table 1). Their findings met the Japan Diabetes Society Diagnostic Criteria for SPIDDM.9 Patients with SPIDDM with heavy alcohol use and inflammatory bowel diseases were excluded. The causes of death of the 19 age-matched control subjects with no diabetes (ND-1 to ND-19, Table 1) were as follows: pneumonia (n = 1), chronic renal failure (n = 2), cerebral infarction (n = 1), acute myocardial infarction (n = 1), intestinal bleeding (n = 1), duodenal cancer (n = 6), gastrinoma (n = 1), colon cancer (n = 1), and biliary cancer (n = 4). No patients received treatment with glucocorticoids.

Tissue Preparation and Histochemical and Immunohistochemical Analyses

The tail and body part of each pancreas were obtained for pathological analyses of islet morphology, pancreatic ductal changes, and parenchymal changes. For quantification analyses including the beta cell area, insulin factors and MNC subtyping in the islets and exocrine pancreatic tissues were performed on the pancreatic tissues from the midpoint of the pancreas to the position one-quarter of the distance to the end of the pancreatic tail, because this part is regarded as fairly representative of the morphometric parameters of the entire pancreas.21 Pancreatic tissues were 4% formalin fixed and paraffin embedded. Methods for immunohistochemical analyses on MNCs for CD subtyping, class I MHC hyperexpression, expressions of innate immune receptors

| Case Subject | Age, y | Sex | Duration of Diabetes, y | GADAbs, U/mL/JDF U | Pancreatic Weight, g | C-Peptide, ng/mL | Body Mass Index, kg/m² | Treatment for Diabetes | Non–Insulin-Requiring Period, y | Cause of Death |
|--------------|--------|-----|------------------------|-------------------|---------------------|-----------------|----------------------|----------------------|-----------------------------|------------------|
| SPIDDM       |        |     |                        |                   |                     |                 |                      |                      |                             |                  |
| SP-1         | 56     | F   | 3                      | 12.5/5            | 30                  | 0.5             | 19.7                 | Insulin              | 1.5             | Gastrointestinal bleeding   |
| SP-2         | 58     | F   | 21                     | 3.4/ND            | 20.5                | 1.5             | 19.2                 | Insulin              | 9               | Meningitis                  |
| SP-3         | 56     | M   | 10                     | 3.4/ND            | 23                  | 1.8             | 20.2                 | Insulin              | 10              | Gastric cancer              |
| SP-4         | 42     | M   | 17                     | 4.2/ND            | 28                  | 2.8             | 20.4                 | Insulin              | 12              | Esophageal cancer           |
| SP-5         | 43     | M   | 13                     | 4.6/ND            | 31                  | 1.17            | 21.1                 | Insulin              | 10              | Small intestinal cancer     |
| SP-6         | 68     | F   | 8                      | 398.0/10          | 45                  | <0.02           | 18.2                 | Insulin              | 1.2             | Chronic renal failure       |
| SP-7         | 75     | M   | 11                     | 12.8/5            | 35.5                | 0.14            | 21.2                 | Insulin              | 0.8             | Esophageal cancer           |
| SP-8         | 87     | M   | 14                     | 5.8/5             | 18.4                | <0.05           | 24.3                 | Insulin              | 1               | Myocardial infarction,      |
| SP-9         | 55     | F   | 16                     | 23.1/ND           | 33                  | <0.1            | 19.1                 | Insulin              | 10.1            | Chronic renal failure       |
| SP-10        | 65     | F   | 0.3                    | 151/+*            | ND                  | 9 μg/d¹        | 26                   | Insulin              | 0.3             | NA²                        |
| SP-11        | 56     | F   | 17                     | 3.4/5             | 24.9                | 0.5             | 16.9                 | Insulin              | 5.8             | Cerebral infarction,         |
| SP-12        | 77     | F   | 24                     | 3.5/5             | 40                  | 0.6             | 17.2                 | Insulin              | 3.5             | Acute respiratory distress, |

Mean (SD) 62 (14) M/F: 5/7 12.0 (6.9) 52.1 (116.6) 29.9 (8.2) 0.82 (0.89) 20.3 (2.7) 5.4 (4.5) 0.3–12.0
Range 42–87 0.3–24 3.4–398.0/5–10 18.4–40.0 0–2.8 17.2–26.0

Mean (SD) 67 (7) M/F: 10/9 79.2 (8.8) 21.7 (2.9) — — See the text

 NA indicates not applicable; ND, not detected.

*Positive for IA-2Ab.
¹Twenty-four-hour urine C-peptide (normal, 16–120 μg/d).
²Biopsied sample.
³Nondiabetic control.

| Case Subject | Age, y | Sex | Duration of Diabetes, y | GADAbs, U/mL/JDF U | Pancreatic Weight, g | C-Peptide, ng/mL | Body Mass Index, kg/m² | Treatment for Diabetes | Non–Insulin-Requiring Period, y | Cause of Death |
|--------------|--------|-----|------------------------|-------------------|---------------------|-----------------|----------------------|----------------------|-----------------------------|------------------|
| SPIDDM       |        |     |                        |                   |                     |                 |                      |                      |                             |                  |
| SP-1         | 56     | F   | 3                      | 12.5/5            | 30                  | 0.5             | 19.7                 | Insulin              | 1.5             | Gastrointestinal bleeding   |
| SP-2         | 58     | F   | 21                     | 3.4/ND            | 20.5                | 1.5             | 19.2                 | Insulin              | 9               | Meningitis                  |
| SP-3         | 56     | M   | 10                     | 3.4/ND            | 23                  | 1.8             | 20.2                 | Insulin              | 10              | Gastric cancer              |
| SP-4         | 42     | M   | 17                     | 4.2/ND            | 28                  | 2.8             | 20.4                 | Insulin              | 12              | Esophageal cancer           |
| SP-5         | 43     | M   | 13                     | 4.6/ND            | 31                  | 1.17            | 21.1                 | Insulin              | 10              | Small intestinal cancer     |
| SP-6         | 68     | F   | 8                      | 398.0/10          | 45                  | <0.02           | 18.2                 | Insulin              | 1.2             | Chronic renal failure       |
| SP-7         | 75     | M   | 11                     | 12.8/5            | 35.5                | 0.14            | 21.2                 | Insulin              | 0.8             | Esophageal cancer           |
| SP-8         | 87     | M   | 14                     | 5.8/5             | 18.4                | <0.05           | 24.3                 | Insulin              | 1               | Myocardial infarction,      |
| SP-9         | 55     | F   | 16                     | 23.1/ND           | 33                  | <0.1            | 19.1                 | Insulin              | 10.1            | Chronic renal failure       |
| SP-10        | 65     | F   | 0.3                    | 151/+*            | ND                  | 9 μg/d¹        | 26                   | Insulin              | 0.3             | NA²                        |
| SP-11        | 56     | F   | 17                     | 3.4/5             | 24.9                | 0.5             | 16.9                 | Insulin              | 5.8             | Cerebral infarction,         |
| SP-12        | 77     | F   | 24                     | 3.5/5             | 40                  | 0.6             | 17.2                 | Insulin              | 3.5             | Acute respiratory distress, |

Mean (SD) 62 (14) M/F: 5/7 12.0 (6.9) 52.1 (116.6) 29.9 (8.2) 0.82 (0.89) 20.3 (2.7) 5.4 (4.5) 0.3–12.0
Range 42–87 0.3–24 3.4–398.0/5–10 18.4–40.0 0–2.8 17.2–26.0

Mean (SD) 67 (7) M/F: 10/9 — Negative/ND 79.2 (8.8) ND 21.7 (2.9) — — See the text

*Positive for IA-2Ab.
¹Twenty-four-hour urine C-peptide (normal, 16–120 μg/d).
²Biopsied sample.
³Nondiabetic control.

NA indicates not applicable; ND, not detected.
Assessment of Islet Inflammation, Insulitis, and Pseudoatrophic Islets

To minimize possible sampling bias for counting CD marker–positive MNCs in the islets, MNC counting was done on serial sections (4 μm thick) stained by triple immunostaining: beta cells and alpha cells were stained by immunofluorescence, and CD marker–positive MNCs were stained by immunoperoxidase staining. More than 10 islets with long diameters of 50 μm or more and with more than 10 alpha cells were stocked in the captured image at magnification ×200 (DP73; Olympus, Tokyo, Japan). Surface markers for CD45, CD3, CD8, CD4, CD20, CD11c, and CD68 were stained on the pancreatic sections.28 L-plastin (LPL), actin-binding molecule crucial for T-cell activation, polarization, and chemotactic actions to target sites,22,23 was also examined using specific antisera.24 L-plastin was identified in inflamed islets of enterovirus-induced fulminant type 1 diabetes (FT1DM) by laser-capture microdissection followed by mass spectrometry.24 In the captured images, the numbers of CD3+ cells stained by immunoperoxidase in the islet areas marked by glucagon-positive cells were counted. Insulitis was defined as an islet with 6 or more CD3+ cells immediately adjacent to (peri-islet area) or within the islet (intra-islet area) in 3 or more islets per pancreas section.25,26 The average number of MNCs in the intra-islet area plus peri-islet area was used as an individual sample for further statistical analysis. Pseudoatrophic islets were defined as islets devoid of beta cells having a long diameter of more than 50 μm.

Estimation of Islet Beta Cell Area and Beta Cell Weight

The beta cell and alpha cell areas were measured morphometrically by Cellsens software (version 1.16; Olympus). At least 5 pancreatic sections were measured, and the average values are expressed as percentages of the total section area (% beta cell area). The estimation of beta cell weight was calculated by (% beta cell area) × pancreatic weight of each case.

Examination of Pancreatic Exocrine Tissue

The number of CD45+ MNCs and CD3+ MNCs in pancreatic exocrine cells was counted in 5 randomly selected photographs of pancreatic sections (1.4 × 1.1 mm²) of each case at ×100 magnification using Cellsens software. The average number of CD45+ and CD3+ MNCs in the exocrine tissues was used as an individual sample for further statistical analysis. Pancreatic ductal changes were examined as reported.15

Examination of Pancreatic Tissue on Amylin-Positive Amyloid Deposition

The presence of amylin-positive amyloid deposition in the islets of the subjects was examined using Congo red staining and specific sera against amylin.27

Assay Methods for GADAbs, ICAs, and Human Leukocyte Antigen

Levels of GADAbs were measured by radioimmunoassay (RSR, Cardiff, Unite Kingdom), and GADAb titers of 1.5 U/mL or higher were judged positive.17 Islet cell antibodies were assayed by immunofluorescence methods.28 Our laboratory participated in the second through fifth International Workshop on Standardization of the ICA Assay, in which the quality of our Lab B was in the highest-quality class (detection limit, <5 JDF U; precision score, 0.65; and specificity, 100%).29 The HLA gene, which encodes cell surface protein responsible for the regulation of the immune system in humans, was typed as previously.3

Ethics

Written informed consent was obtained from the next of kin on behalf of the autopsied patients and from the biopsied patient. All procedures used in this study were approved by the ethics committees of the University of Yamanashi and Toranomon Hospital.

Statistical Analysis

Fisher’s exact test was used to evaluate the frequencies of lesions. Comparisons between groups were performed using the Kruskal-Wallis test and the Mann-Whitney U test. Values are expressed as means (standard deviation [SD]) or medians depicted by box-and-whisker plots. P < 0.05 was considered significant.

RESULTS

Islet Inflammation and Insulitis

Mononuclear cells positive for CD45+ and CD3+ infiltrated the peri-islet and intra-islet areas in all SPIDDM pancreases (Figs. 1A, B). The median frequency of defined insulitis, observed in all 12 SPIDDM pancreases in a patchy distribution, was 14.0%, ranging from 3.5% to 33.3% (n = 524) (Fig. 1C). The cell numbers of CD45+ MNCs in the intra-islet and peri-islet areas correlated well with those of CD3+ MNCs (r = 0.926, P < 0.001), suggesting that the insulitis lesion is mainly composed of CD3+ T-cells. The mean number of CD3+ T-cells in the islets with insulitis was 9 (SD, 5) (range, 6–29). The main subsets of MNCs infiltrating to the islets were CD8+ T-cells and CD68+ macrophages in SPIDDM (Fig. 1D). High proportions of CD8+ and CD68+ cells in peri-islet and intra-islet areas were positive for LPL (Fig. 1E) in SPIDDM. The LPL-positive CD8+ T-cells showed the characteristic “uropod” appearance, indicating that the CD8+ T-cells were activated/polarized and chemotactic to target cells (Fig. 1E) in SPIDDM. These findings suggest that most activated CD8+ T-cells around the islets may target and migrate from peri-islet areas into the islets of SPIDDM, according to the previous findings in enterovirus-induced FT1DM and AT1DM.17,19,20,25,30,31 Insulitis in SPIDDM persisted for long periods after the onset of diabetes (Fig. 1F) and differing previous reports of classic AT1DM.25,30,31 No correlation was found between the frequency of insulitis and titer of GADAbs (Fig. 1G).
FIGURE 1. Islet inflammation in SPIDDM. A, CD45+ (leukocyte common antigen) MNCs (brown, arrowheads) infiltrate in and around the islet demarcated by the dashed line in SPIDDM (case SP-6) (scale bar, 50 μm). B, CD3+ T-cells (brown, arrowheads) are observed in and around the islet demarcated by the dashed line (case SP-3) (scale bar, 50 μm). C, Overall frequencies of insulitis in SPIDDM patients and control subjects with no diabetes with medians depicted by box-and-whisker plots. The box represents the mid 50% of the data, and the high and low whiskers represent the 95th and 5th percentiles. Numbers in parentheses indicate the numbers of individual islets counted. D, The median number of leukocyte subtypes per islet in the SPIDDM pancreas with medians depicted by box-and-whisker plots. *Significantly higher than control subjects with no diabetes. Numbers in parentheses indicate total numbers of individual islets analyzed for each leukocyte marker. $P<0.05$ versus control subjects with no diabetes. E, Merged image of triple immunostaining for LPL (green), CD8 (red), and insulin (blue) in the SPIDDM pancreas. Most CD8+ T-cells double positive for LPL and CD8 (arrowheads stained as yellow) are infiltrated to the islets and show the characteristic “uropod” appearance (inset) (case SP-1) (scale bar, 25 μm). F, There are no differences of insulitis frequencies between SPIDDM patients with short duration and long duration. N.S. indicates not significant. G, Relationship between frequencies of insulitis and titers of GADAbs in SPIDDM.
Enterovirus-Related VP1 Proteins, Innate Immune Cascades, Cytokines, and Islet Amylin-Positive Amyloid

Enterovirus-related VP1 proteins were not detected in any parts of 12 SPIDDM pancreases immunohistochemically. The expressions of innate immune receptors including RIG-I, MDA5, and TLR4 and cytokines including interleukin 18, IFN-γ were not detected in the islet beta cells and exocrine pancreases in all SPIDDM pancreases immunohistochemically. These findings are in contrast to the reports of marked expressions of these molecules in AT1DM30–33 and FT1DM.17,19,32

Amylin-positive amyloid deposition in islets, a marker of T2DM, was not observed immunohistochemically and Congo red staining in SPIDDM and control.

Pancreatic Ductal Changes and Exocrine Tissue Inflammation

Pancreatic Ductal Changes

As many as 75% (9/12) of SPIDDM pancreases had significantly higher frequencies of pancreatic intraepithelial neoplasia (PanIN) than age-matched control subjects with no diabetes: 5% (1/19) (Fig. 3A). The numbers of PanIN-positive pancreatic ducts per centimeter squared of each section were significantly higher than those of control subjects with no diabetes (Fig. 3B). The PanIN grade ranged from PanIN-1A to PanIN-2 (Supplemental Table 1, http://links.lww.com/MPA/A674). The lesions were characterized by tall, columnar, and mucin-rich cells with various degrees of nuclear atypia in the branches and smaller ducts (Fig. 3C). The pancreatic ducts had dilated lumens filled with mucous plaques and sequestrated contents (Fig. 3C), and the pancreatic lobules with PanIN showed chronic pancreatitis and lobular atrophy, whereas lobes without PanIN showed intact acinar tissues (Fig. 3D). Two SPIDDM pancreases without apparent PanIN in the pancreatic sections (cases SP-5 and SP-7) showed dilated pancreatic ducts filled with mucinous materials, pancreatic duct epithelial erosion, and periductal inflammation, suggesting the presence of ductal obstruction and subsequent chronic obstructive pancreatitis caused by occult PanIN at the downstream part of the pancreatic duct (Fig. 3E). The one remaining SPIDDM patient (case SP-10, duration of diabetes 0.3 years) without PanIN lesions had a recent history of recurrent bile stone attacks, and the pancreas biopsied at surgical cholecystectomy showed pancreatic ductal dilation and periductal fibrosis with focal parenchymal atrophy (Figs. 3F, G).
FIGURE 3. Changes in exocrine pancreases in SPIDDM. A, The frequencies of pancreatic intraductal neoplasia (PanIN) lesion in pancreatic duct with 95% confidence interval in SPIDDM and nondiabetic control pancreases. B, The number of PanIN-positive pancreatic ducts in SPIDDM and nondiabetic control pancreases with median depicted by box-and-whisker plots. C, Pancreatic intraductal neoplasia lesion with tall columnar cells and various degrees of atypia is observed (arrowheads, case SP-2). Note marked inflammatory cells, fibrosis, and atrophied exocrine parenchyma and intraductal mucous contents (asterisks) (hematoxylin-eosin [HE] staining, original magnification ×200; scale bar, 50 μm). D, Pancreatic exocrine lobe with PanIN (asterisks) shows extensive lobular atrophy demarcated by arrowheads, whereas the adjacent lobe without PanIN appears nonatrophiied (demarcated by arrows) (case SP-2) (HE staining, original magnification ×40; scale bar, 250 μm; B–D). E, Changes in pancreatic exocrine tissue without apparent PanIN (case SP-5). Intraductal mucinous contents (arrow) and the erosive pancreatic ductal wall (arrowheads) indicate ductal fluid obstruction likely due to occult PanIN downstream of the pancreatic duct. F, Lobular atrophy and periductal fibrosis (arrowheads) in an SPIDDM patient (case SP-10) with a history of recurrent bile stone attacks. G, Another part of a section of case SP-10 shows pancreatic ductal dilation and periductal fibrosis (asterisks) indicating presence of intraductal hyperpressure presumably due to recurrent pancreatic ductal obstruction or narrowing by stacked bile stones in the duodenal papilla (HE staining, original magnification ×200; scale bar, 50 μm). H, Increased numbers of CD45+ and CD3+ MNCs in exocrine pancreatic tissues (red box) indicate extensive exocrine pancreatic inflammation in SPIDDM. White box: control subjects with no diabetes.
Pancreatic Exocrine Inflammation

Exocrine pancreases with SPIDDM showed extensive inflammation, especially in the lobes with PanIN lesions (Figs. 3C, D). The numbers of CD45+ and CD3+ MNCs infiltrated into the exocrine pancreas were increased in SPIDDM (Fig. 3H).

MHC Class I Hyperexpression

Hyperexpression of MHC class I on beta cells was observed in all cases with SPIDDM (Figs. 4A, B). Percent MHC class I–positive islet beta cells were significantly low in 19 age-matched nondiabetic control pancreases (Figs. 4C–E).

DISCUSSION

The distinct pathological findings of the pancreases of SPIDDM were as follows.

First, CD3+ T-cell-dominant patchy islet inflammation/insulitis was observed in all cases with SPIDDM. Insulitis persisted for a long time after onset. CD8+ T-cells expressed LPL and were shaped in a characteristic “uropod” appearance, showing that the T-cells were activated and homing to islets, even in long-standing cases (Fig. 1F). In contrast, insulitis commonly subsides after several months to years with a decreased volume of beta cells in typical AT1DM and FT1DM.18,25,30–34 Second, beta cells remained long after onset of diabetes in SPIDDM pancreases. In contrast, beta cell volume decreases rapidly with the duration of diabetes, and beta cells are mostly destroyed after long duration of diabetes in AT1DM.35,36 Third, significantly high frequencies of PanIN lesions and extensive chronic pancreatitis were observed in SPIDDM. In our previous report,15 the frequencies of PanIN lesion in AT1DM and T2DM were 10% (1/10) and 13% (2/15), respectively, significantly lower than the values of SPIDDM. Pancreatic intraepithelial neoplasia lesions secrete mucinous products, and or PanIN lesions themselves obstruct or narrow the pancreatic ducts, initiating intraductal hyperpressure and chronic pancreatitis causing pancreatic lobular atrophy.37 No MHC class I hyperexpression and no pseudoatrophic islets were found in the pancreases of control subjects with no diabetes. It is therefore possible that PanIN lesion, insulitis, MHC class I hyperexpression, and pseudoatrophic islets are distinct features of SPIDDM pancreas. Finally, evidence of enterovirus infection (VP1 protein expression), activation of innate immune cascades (MDA5, RIG-I, and TLR4), and expression of the cytokine axis (IFN–γ, IL-18), which was detected in FT1DM and AT1DM,17,19,32 were not observed in the islet cells of SPIDDM. Similar to FT1DM and AT1DM, pseudoatrophic islets devoid of beta cells with preserved non-beta cells were observed in SPIDDM, indicating that the destruction of islet cells is caused by beta cell–specific mechanisms. These findings in SPIDDM pancreases support the concept that the initial mechanisms of beta cell destruction are different from viral infection–triggered FT1DM and potentially from AT1DM, involving innate and autoimmune mechanisms.17,19,30–34

Our hypothesis regarding beta cell destruction in SPIDDM is that pancreatic ductal hyperpressure and stasis/leakage of pancreatic digestive fluid induced by PanIN lesions, which were observed in a high proportion of SPIDDM cases, may cause chronic pancreatitis.37 An extended and persisting/recurrent

![FIGURE 4. The MHC class I hyperexpression in SPIDDM. A, MHC class I hyperexpression (green) in SPIDDM pancreas (case SP-1) (scale bar: 50 μm). B, Merged image of triple immunostaining for MHC class I (green), insulin (blue), and glucagon (red) in SPIDDM pancreas (case SP-1). Mainly beta cells show hyperexpression of MHC class I. C, MHC class I staining (green) in nondiabetic control. D, Merged image of triple immunostaining for MHC class I (green), insulin (blue), and glucagon (red) in nondiabetic control. E, The percentage of MHC class I hyperexpression of islet beta cells in SPIDDM and control pancreases with medians depicted by box-and-whisker plots. Numbers in parenthesis indicate counted islet beta cell number.](image-url)
inflammatory milieu in the islets and/or the exocrine pancreas potentially induces release of self-antigens from islets and the exocrine pancreas and promotes islet MHC class I hyperexpression of islet beta cells in SPIDDM. Ballooning and dilation of the pancreatic duct by pancreatic ductal hyperpressure in SPIDDM were demonstrated by endoscopic retrograde pancreatography. 38 One of the authors (T.K.) evaluated a non-insulin-requiring GADAb-negative 58-year-old woman with diabetes, who had pancreatic ductal cystic lesion with epithelial hyperplasia (PanIN) and type 1 diabetes–susceptible HLA haplotypes (HLA-DR 9/9). In this case, GADAb became negative to positive during the follow-up period. 39 After the seroconversion, C-peptide responses decreased, and PanIN lesion advanced progressively to the features of intraductal papillary mucinous neoplasm. Considering together with these findings, combined processes including MHC class I hyperexpression associated with exocrine inflammation around the islet caused by PanIN lesion and genetic predisposition (ie, HLA gene, Supplemental Table 1, http://links.lww.com/MPA/A674) may be required to continue to activate, attract, and induce homing of autoreactive CD8+ T-cells to islet beta cells through a bystander mechanism, 40,41 leading to full-blown insulitis and complete beta cell destruction in SPIDDM. All SPIDDM patients typed for HLA (Supplemental Table 1, http://links.lww.com/MPA/A674) had susceptible one for type 1 diabetes in Japanese population. 7

An absence of amylin-positive amyloid depositions in SPIDDM pancreases, which are closely related to T2DM, supports the concept that the mechanisms of beta cell damage of SPIDDM are different from those in T2DM. 27 The present study had a limitation due to its small sample size, especially samples from short duration of diabetes. Its strength was that most of the cases were recruited from our cohort in which patients were followed up throughout their clinical courses, and clinical data including fasting C-peptide levels, the exact duration in which patients were followed up, and body mass index were obtained. 3,7,8,17–20

ACKNOWLEDGMENTS

The authors thank the late Dr Taro Maruyama, Saitama Social Insurance Hospital, for his generous assistance in obtaining the study samples and Fumie Takano, Okinaka Memorial Institute for Medical Research, for her excellent secretarial work.

REFERENCES

1. Kobayashi T, Itoh T, Kosaka K, et al. Time course of islet cell antibodies and β-cell function in non–insulin-dependent stage of type 1 diabetes. Diabetes. 1987;36:510–517.
2. Kobayashi T, Nakanishi K, Sugimoto T, et al. Maleness as risk factor for slowly progressive IDDM. Diabetes Care. 1989;12:7–11.
3. Kobayashi T, Tanemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993;16:780–788.
4. Kobayashi T. Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM—the clinical characteristics and pathogenesis of the syndrome. Diabetes Res Clin Pract. 1994;suppl 24: S95–S99.
5. Stenström G, Gottsäter A, Bakrhatde E, et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes. 2005;54 (suppl 2):S68–S72.
6. Leslie RD, Palmer J, Schlott NC, et al. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia. 2016;59:13–20.
7. Kobayashi T, Nakanishi K, Okubo M, et al. GAD antibodies seldom disappear in slowly progressive IDDM. Diabetes Care. 1996;19:1031.
8. Tanaka S, Ohmori M, Awata T, et al. Committee on Type 1 Diabetes. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus of the Japan Diabetes Society. Diabetes Ther. 2015;6:1–7.
9. Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab. 2008;93:2115–2121.
10. Hirata T, Shimada A, Morimoto J, et al. Slowly progressive type 1 diabetes treated with metformin for five years after onset. Intern Med. 2013;52:2635–2637.
11. Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014;99:E876–E880.
12. Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8:1123–1134.
13. Shimada A, Imizu Y, Morinaga S, et al. T-cell insulinis found in anti-GAD65+ diabetes with residual beta-cell function. A case report. Diabetes Care. 1999;22:615–617.
14. Rodriguez-Calvo T, Ekwoll O, Amirian N, et al. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes. 2014;63:3880–3890.
15. Kobayashi T, Aida K, Fukui T, et al. Pancreatic ductal hyperplasia/dysplasia with obstructive chronic pancreatitis: an association with reduced pancreatic weight in type 1 diabetes. Diabetologia. 2016;59:865–867.
16. Campbell-Thompson ML, Schatz DA, Kaddis JS, et al. Pancreatic duct hyperplasia/dysplasia in type 1 diabetes and pancreatic weight in individuals with and without diabetes. Reply to Kobayashi T, Aida K, Fukui T et al [letter] and Saisho Y [letter]. Diabetologia. 2016;59:870–872.
17. Tanaka S, Nishida Y, Aida K, et al. Enterovirus infection, CXCL chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes. 2009;58:2285–2291.
18. Tanaka S, Kobayashi T, Mornmotsu T. A novel subtype of type 1 diabetes mellitus. N Engl J Med. 2000;342:1835–1837.
19. Aida K, Nishida Y, Tanaka S, et al. RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. Diabetes. 2011;60:884–889.
20. Nakanishi K, Kobayashi T, Miyashita H, et al. Relationships among residual beta cells, exocrine pancreas, and islet cell antibodies in insulin-dependent diabetes mellitus. Metabolism. 1993;42:196–203.
21. Saito K, Iwama N, Takahashi T. Morphometrical analysis on topographical difference in size distribution, number and volume of islets in the human pancreas. Tohoku J Exp Med. 1978;124:177–186.
22. Samstag Y, Eibert SM, Klemke M, et al. Actin cytoskeletal dynamics in T lymphocyte activation and migration. J Leukoc Biol. 2003;73:30–48.
23. Morley SC. The actin-binding protein L-plastin supports T-cell motility and activation. Immunol Res. 2013;52:48–62.
24. Nishida Y, Aida K, Kihara M, et al. Antibody–validated proteins in inflamed islets of fulminant type 1 diabetes profiled by laser-capture microdissection followed by mass spectrometry. PLoS One. 2014;9:e107664.
25. Campbell-Thompson M, Fu A, Kaddis JS, et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes. 2016;65:719–731.
26. Campbell-Thompson ML, Atkinson MA, Butler AE, et al. The diagnosis of insulitis in human type 1 diabetes. Diabetologia. 2013;56:2541–2543.
27. Sugawara K, Kobayashi T, Nakanishi K, et al. Marked islet amyloid polypeptide–positive amyloid deposition: a possible cause of severely insulin-deficient diabetes mellitus with atrophied exocrine pancreas. Pancreas. 1993;8:312–315.
28. Kobayashi T, Sugimoto T, Itoh T, et al. The prevalence of islet cell antibodies in Japanese insulin-dependent and non-insulin-dependent diabetic patients studied by indirect immunofluorescence and by a new method. *Diabetes*. 1986;35:335–340.

29. Bonifacio E, Boitard C, Gleichmann H, et al. Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. *Diabetologia*. 1990;33:731–736.

30. 't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. *Islets*. 2011;3:131–138.

31. Roep BO. Insulitis revisited. *Diabetes*. 2016;65:545–547.

32. Roep BO, Kleijwegt FS, van Halteren AG, et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. *Clin Exp Immunol*. 2010;159:338–343.

33. Richardson SJ, Morgan NG, Foulis AK. Pancreatic pathology in type 1 diabetes mellitus. *Endocr Pathol*. 2014;25:80–92.

34. Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. *N Engl J Med*. 2000;342:301–307.

35. Richardson SJ, Willcox A, Bone AJ, et al. Immunopathology of the human pancreas in type 1 diabetes. *Semin Immunopathol*. 2011;33:9–21.

36. Oram RA, McDonald TJ, Shields BM, et al. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. *Diabetes Care*. 2015;38:323–328.

37. Talamini G, Zamboni G, Salvia R, et al. Intraductal papillary mucinous neoplasms and chronic pancreatitis. *Pancreatology*. 2006;6:626–634.

38. Nakanishi K, Kobayashi T, Miyashita H, et al. Exocrine pancreatic ductograms in insulin-dependent diabetes mellitus. *Am J Gastroenterol*. 1994;89:762–766.

39. Kobayashi T. [Slowly progressive IDDM: natural history and intervention strategies]. [Article in Japanese]. *Tounyoubyougaku No Shinnpo*. 2011;45:41–45.

40. Pane JA, Coulson BS. Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes. *Diabetologia*. 2015;58:1149–1159.

41. Richardson SJ, Rodriguez-Calvo T, Gerling IC, et al. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. *Diabetologia*. 2016;59:2488–2498.